Comparisons of efficacy of different pulmonary surfactants for the treatment of neonatal respiratory distress syndrome.
Objective: To analyze the therapeutic effect of pulmonary surfactant (PS) in combination with nasal continuous positive airway pressure (NCPAP) therapy on neonatal respiratory distress syndrome (NRDS).
KEY WORDS: Neonate, Pulmonary surfactant, Respiratory distress syndrome.
Study on early application of pulmonary surfactant combined with assisted ventilation in the treatment of respiratory distress syndrome in premature infants.
Clinical study on nasal continuous positive airway pressure (NCPAP) combined with pulmonary surfactant in treatment of neonatal respiratory distress syndrome.
Pulmonary surfactant and nasal continuous positive airway pressure ventilation in the treatment of neonatal respiratory distress syndrome.
Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis.
The patent provides coverage for compositions that employ a combination of certain pulmonary surfactants
with a broad array of protease inhibitors, administered as either a liquid or aerosol, for treating pulmonary inflammation, the company said.
Discovery believes that through its technology, pulmonary surfactants
have the potential, for the first time, to be developed into a series of respiratory therapies for critical care and other hospitalized patients where there are few or no approved therapies available.